CD40LG as a Prognostic Molecular Marker Regulates Tumor Microenvironment Through Immune Process in Breast Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Gupta S, Roy A, Dwarakanath BS. Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front Oncol. 2017;7:68.
   PubMed Web of Science ®Google Scholar
• Mittal S, Brown NJ, Holen I. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn. 2018;18(3):227–243. doi:10.1080/14737159.2018.1439382
   PubMed Web of Science ®Google Scholar
• Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev. 2018;37(4):577–597. doi:10.1007/s10555-018-9768-3
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Li Y, Wang JS, Zhang T, Wang HC, Li LP. Identification of new therapeutic targets for gastric cancer with bioinformatics. Front Genet. 2020;11:865. doi:10.3389/fgene.2020.00865
   PubMed Web of Science ®Google Scholar
• Xiong Y, Wang K, Zhou H, Peng L, You W, Fu Z. Profiles of immune infiltration in colorectal cancer and their clinical significant: a gene expression-based study. Cancer Med. 2018;7(9):4496–4508. doi:10.1002/cam4.1745
   PubMed Web of Science ®Google Scholar
• Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep. 2018;8(1):6220. doi:10.1038/s41598-018-24437-5
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. doi:10.1016/j.biopha.2017.08.003
   PubMed Web of Science ®Google Scholar
• Liu J, Wei Y, Wu Y, et al. ATP2C2 has potential to define tumor microenvironment in breast cancer. Front Immunol. 2021;12:657950. doi:10.3389/fimmu.2021.657950
   PubMed Web of Science ®Google Scholar
• Chen Y, Meng Z, Zhang L, Liu F. CD2 is a novel immune-related prognostic biomarker of invasive breast carcinoma that modulates the tumor microenvironment. Front Immunol. 2021;12:664845. doi:10.3389/fimmu.2021.664845
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang G, Sui Y, et al. CD52 is a prognostic biomarker and associated with tumor microenvironment in breast cancer. Front Genet. 2020;11:578002. doi:10.3389/fgene.2020.578002
   PubMed Web of Science ®Google Scholar
• THE HUMAN PROTEIN ATLAS. Expression of CD2 in breast cancer. Available from: https://www.proteinatlas.org/ENSG00000116824-CD2/pathology/breast+cancer. Accessed July 20, 2021.
   Google Scholar
• Baik SH, Gallo LC, Wells KJ. Patient navigation in breast cancer treatment and survivorship: a systematic review. J Clin Oncol. 2016;34(30):3686–3696. doi:10.1200/JCO.2016.67.5454
   PubMed Web of Science ®Google Scholar
• Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomedicine. 2017;12:5879–5892. doi:10.2147/IJN.S123437
   PubMed Web of Science ®Google Scholar
• Bense RD, Sotiriou C, Piccart-Gebhart MJ, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst. 2017;109(1). doi:10.1093/jnci/djw192.
   PubMedGoogle Scholar
• García-Aranda M, Redondo M. Immunotherapy: a challenge of breast cancer treatment. Cancers. 2019;11(12):1822. doi:10.3390/cancers11121822
   PubMed Web of Science ®Google Scholar
• Law AM, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer. 2017;24(4):R123–R144. doi:10.1530/ERC-16-0404
   PubMed Web of Science ®Google Scholar
• Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 2017;37(2–6):371–420. doi:10.1615/CritRevImmunol.v37.i2-6.100
   PubMed Web of Science ®Google Scholar
• Loskog A, Tötterman TH. CD40L - A multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007;7(1):23–28. doi:10.2174/187153007780059432
   PubMedGoogle Scholar
• Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;7(3):691–703.
   PubMed Web of Science ®Google Scholar
• Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood. 1999;93(9):2999–3007. doi:10.1182/blood.V93.9.2999
   PubMed Web of Science ®Google Scholar
• Zhu D, Chen C, Purwanti YI, et al. Induced pluripotent stem cell-derived neural stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer. Hum Gene Ther. 2014;25(8):747–758. doi:10.1089/hum.2013.160
   PubMed Web of Science ®Google Scholar
• Purwanti YI, Chen C, Lam DH, et al. Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model. Stem Cells Transl Med. 2014;3(8):923–935. doi:10.5966/sctm.2013-0140
   PubMed Web of Science ®Google Scholar
• Kim H, Kim Y, Bae S, et al. Direct interaction of CD40 on tumor cells with CD40L on T cells increases the proliferation of tumor cells by enhancing TGF-β production and Th17 differentiation. PLoS One. 2015;10(5):e0125742. doi:10.1371/journal.pone.0125742
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Linde N, Casanova-Acebes M, Sosa MS, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9(1):21. doi:10.1038/s41467-017-02481-5
   PubMed Web of Science ®Google Scholar
• Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 2018;70:178–189. doi:10.1016/j.ctrv.2018.08.010
   PubMed Web of Science ®Google Scholar
• Governa V, Brittoli A, Mele V, et al. A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo. Oncoimmunology. 2019;8(5):e1568162. doi:10.1080/2162402X.2019.1568162
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry A, Ho CS, Maxwell T, et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 2007;97(9):1251–1259. doi:10.1038/sj.bjc.6604018
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry A, Schmidt CW, López JA. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res. 2006;8(1):402. doi:10.1186/bcr1386
   PubMed Web of Science ®Google Scholar
• Sadeghlar F, Vogt A, Mohr RU, et al. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Cancer Immunol Immunother. 2021;70(5):1451–1464. doi:10.1007/s00262-020-02746-x
   PubMed Web of Science ®Google Scholar
• Jachetti E, Cancila V, Rigoni A, et al. Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol Res. 2018;6(5):552–565. doi:10.1158/2326-6066.CIR-17-0385
   PubMed Web of Science ®Google Scholar
• Danelli L, Frossi B, Gri G, et al. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol Res. 2015;3(1):85–95. doi:10.1158/2326-6066.CIR-14-0102
   PubMed Web of Science ®Google Scholar
• Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer. 2003;107(1):159–163. doi:10.1002/ijc.11340
   PubMed Web of Science ®Google Scholar
• Kankkunen JP, Harvima IT, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer. 1997;72(3):385–388. doi:10.1002/(SICI)1097-0215(19970729)72:3<385::AID-IJC1>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar